Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2017 16:46 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study

PHILADELPHIA and OXFORD, United Kingdom, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, submitted updated data from its...
December 05, 2017 17:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Data to be Presented at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy in Multiple Myeloma Pilot Study

PHILADELPHIA, Pa. and OXFORD, UK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will have updated data from its completed...
November 10, 2017 08:58 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Presents Study Designs for Ongoing MAGE-A4 and NY-ESO SPEAR T-cell Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

PHILADELPHIA and OXFORD, U.K., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, is presenting two trials in progress posters...
November 09, 2017 08:00 ET | Source: Adaptimmune Therapeutics plc

NY-ESO Data Presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting Confirm Potential of Adaptimmune’s SPEAR T-Cell Therapy

PHILADELPHIA and OXFORD, United Kingdom, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, released updated data from the...
November 06, 2017 08:09 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune marks Official Opening of U.K. Headquarters

PHILADELPHIA and OXFORD, U.K., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it will host an official...
November 03, 2017 14:22 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Present Two Trials in Progress Posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

PHILADELPHIA and OXFORD, U.K., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it will present two...
November 03, 2017 14:17 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Data to be Presented in an Oral Presentation and a Trial in Progress Poster at the Connective Tissue Oncology Society (CTOS) Annual Meeting

PHILADELPHIA and OXFORD, U.K., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that new data will be...
November 02, 2017 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Reports Third Quarter 2017 Financial Results and Business Updates

– GlaxoSmithKline plc (LSE/NYSE:GSK) exercised its option to license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program –– Adaptimmune will receive up...
October 27, 2017 11:11 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Report Third Quarter 2017 Financial Results on November 2, 2017

PHILADELPHIA and OXFORD, U.K., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the...
October 23, 2017 17:51 ET | Source: Adaptimmune Therapeutics plc

Sébastien Desprez Joins Adaptimmune as Vice President of Communications and Investor Relations

PHILADELPHIA and OXFORD, U.K., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Sébastien Desprez has...